Anterior|Próximo

Avanços na compreensão das bactérias residentes em tumores e sua aplicação na terapia do câncer

  • role： First author第一作者
  • Affiliation：

    Centre for Biological Science and Technology, Key Laboratory of Cell Proliferation and Regulation Biology of Ministry of Education, Department of Biology, Faculty of Arts and Sciences, Guangdong Zhuhai-Macao Joint Biotech Laboratory, Beijing Normal University, Zhuhai 519087, Guangdong, China

    Department of Pathology, the Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai 519000, Guangdong, China

Yi-Chen Luo12,  
  • Affiliation：

    Guangdong-Hong Kong-Macao University Joint Laboratory of Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai 519000, Guangdong, China

Xiu-Ting Huang3,  
  • Affiliation：

    Guangdong-Hong Kong-Macao University Joint Laboratory of Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai 519000, Guangdong, China

Rui Wang3,  
  • Affiliation：

    Department of Pathology, the Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai 519000, Guangdong, China

Yu-Jing Lin2,  
  • Affiliation：

    Guangdong-Hong Kong-Macao University Joint Laboratory of Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai 519000, Guangdong, China

    School of Medicine, Sun Yat-Sen University, Shenzhen 518055, Guangdong, China

Jia-Xin Sun34,  
  • Affiliation：

    Faculty of Applied Sciences, Macao Polytechnic University, Macau SAR 999078, China

Ke-Feng Li5,  
  • Affiliation：

    Department of Otolaryngology, Yong Loo Lin School of Medicine, National University Health System, National University of Singapore, Singapore 119228, Singapore

De-Yun Wang6,  
  • Affiliation：

    Guangdong-Hong Kong-Macao University Joint Laboratory of Interventional Medicine, the Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai 519000, Guangdong, China

Yan Yan3,  
  • role： Corresponding author通信作者
  • Affiliation：

    Centre for Biological Science and Technology, Key Laboratory of Cell Proliferation and Regulation Biology of Ministry of Education, Department of Biology, Faculty of Arts and Sciences, Guangdong Zhuhai-Macao Joint Biotech Laboratory, Beijing Normal University, Zhuhai 519087, Guangdong, China

  • Email：ykqiao@bnu.edu.cn
  • Introduction：* Yong-Kang Qiao ykqiao@bnu.edu.cn
Yong-Kang Qiao1*

Resumo

Os avanços recentes no sequenciamento de próxima geração e bioinformática têm impulsionado um interesse crescente nos papéis distintos da microbiota intratumoral, particularmente bactérias intracelulares, durante a evolução do tumor. Essas bactérias aumentam a probabilidade de metástase, desempenham papéis importantes na progressão do câncer e impactam a eficácia da terapia. Esta revisão explora as fontes, os mecanismos de invasão nas células cancerígenas e as potenciais estratégias de sobrevivência das bactérias intracelulares em neoplasmas, destacando seu papel crucial no desenvolvimento do câncer. Também examinamos a heterogeneidade e a interação intrincada das comunidades microbianas intratumorais com células imunológicas e cancerígenas, enfatizando seus potenciais papéis na modulação da genética, epigenética e imunidade do hospedeiro. Finalmente, discutimos abordagens inovadoras para direcionar bactérias intracelulares, particularmente sistemas de entrega de fármacos projetados e biologia sintética, que visam aumentar a eliminação bacteriana, reprogramar o microambiente imune tumoral e melhorar a eficácia da quimioterapia e imunoterapia. Como resultado, esta revisão fornece novos insights para orientar futuras investigações e apoiar o desenvolvimento de intervenções baseadas na microbiota em oncologia.

Palavras-chave

Microbioma intratumoral;Bactérias intracelulares;Progressão do câncer;Modulação imunológica;Terapêuticas contra o câncer

References

  1. 1..
    Ma Z,Zuo T,Frey N,Rangrez AY. A systematic framework for under-standing the microbiome in human health and disease: from basic principles to clinical translation. Signal Transduct Target Ther.2024;9(1):237.
  2. 2..
    Sender R,Fuchs S,Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533.
  3. 3..
    Sender R,Fuchs S,Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell. 2016;164(3):337-40.
  4. 4..
    Jyoti ,Dey P. Mechanisms and implications of the gut microbial modulation of intestinal metabolic processes. NPJ Metab Health Dis.2025;3(1):24.
  5. 5..
    Sardar P,Beresford-Jones BS,Xia W,Shabana O,Suyama S,Ramos RJF, et al. Gut microbiota-derived hexa-acylated lipopolysaccha-rides enhance cancer immunotherapy responses. Nat Microbiol.2025;10(3):795-807.
  6. 6..
    Scharschmidt TC,Segre JA. Skin microbiome and dermatologic disor-ders. J Clin Invest. 2025;135(3):e184315.
  7. 7..
    Joos R,Boucher K,Lavelle A,Arumugam M,Blaser MJ,Claesson MJ, et al.Examining the healthy human microbiome concept. Nat Rev Microbiol.2025;23(3):192-205.
  8. 8..
    Rodriguez RM,Khadka VS,Menor M,Hernandez BY,Deng Y. Tissue-associated microbial detection in cancer using human sequencing data. BMC Bioinformatics. 2020;21(Suppl 9):523.
  9. 9..
    Yuan S,Fang C,Leng WD,Wu L,Li BH,Wang XH, et al. Oral microbiota in the oral-genitourinary axis: identifying periodontitis as a potential risk of genitourinary cancers. Mil Med Res. 2021;8(1):54.
  10. 10..
    Nejman D,Livyatan I,Fuks G,Gavert N,Zwang Y,Geller LT, et al. The human tumor microbiome is composed of tumor type-specific intra-cellular bacteria. Science. 2020;368(6494):973-80.
  11. 11..
    Jenkins SV,2ndRobeson MS,Griffin RJ,Quick CM,Siegel ER,Can-non MJ, et al. Gastrointestinal tract dysbiosis enhances distal tumor progression through suppression of leukocyte trafficking. Cancer Res.2019;79(23):5999-6009.
  12. 12..
    Calcinotto A,Brevi A,Chesi M,Ferrarese R,Garcia Perez L,Grioni M, et al. Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nat Commun.2018;9(1):4832.
  13. 13..
    Zitvogel L,Fidelle M,Kroemer G. Long-distance microbial mechanisms impacting cancer immunosurveillance. Immunity. 2024;57(9):2013-29.
  14. 14..
    Wong-Rolle A,Wei HK,Zhao C,Jin C. Unexpected guests in the tumor microenvironment: microbiome in cancer. Protein Cell.2021;12(5):426-35.
  15. 15..
    Xie Y,Xie F,Zhou X,Zhang L,Yang B,Huang J, et al. Microbiota in tumors: from understanding to application. Adv Sci (Weinh).2022;9(21):e2200470.
  16. 16..
    Madi N,Chen D,Wolff R,Shapiro BJ,Garud NR. Community diversity is associated with intra-species genetic diversity and gene loss in the human gut microbiome. Elife. 2023;12:e78530.
  17. 17..
    Piccinno G,Thompson KN,Manghi P,Ghazi AR,Thomas AM,Blanco-Miguez A, et al. Pooled analysis of 3, 741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial bio-markers of colorectal cancer. Nat Med. 2025. .
  18. 18..
    Johnston CD,Bullman S. Bacteria-derived L-lactate fuels cervical cancer chemoradiotherapy resistance. Trends Cancer. 2024;10(2):97-9.
  19. 19..
    Wu H,Leng X,Liu Q,Mao T,Jiang T,Liu Y, et al. Intratumoral microbiota composition regulates chemoimmunotherapy response in esophageal squamous cell carcinoma. Cancer Res. 2023;83(18):3131-44.
  20. 20..
    Geller LT,Barzily-Rokni M,Danino T,Jonas OH,Shental N,Nejman D, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science.2017;357(6356):1156-60.
  21. 21..
    Joo JE,Chu YL,Georgeson P,Walker R,Mahmood K,Clendenning M, et al. Intratumoral presence of the genotoxic gut bacteria pks+ E. coli, Enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer. Br J Cancer. 2024;130(5):728-40.
  22. 22..
    Barot SV,Sangwan N,Nair KG,Schmit SL,Xiang S,Kamath S, et al.Distinct intratumoral microbiome of young-onset and average-onset colorectal cancer. EBioMedicine. 2024;100:104980.
  23. 23..
    Bohm MS,Joseph SC,Sipe LM,Kim M,Leathem CT,Mims TS, et al. The gut microbiome enhances breast cancer immunotherapy following bariatric surgery. JCI Insight. 2025;10(11):e187683.
  24. 24..
    Cao M,Deng Y,Hao Q,Yan H,Wang QL,Dong C, et al. Single-cell transcriptomic analysis reveals gut microbiota-immunotherapy synergy through modulating tumor microenvironment. Signal Transduct Target Ther. 2025;10(1):140.
  25. 25..
    Rahal Z,Liu Y,Peng F,Yang S,Jamal MA,Sharma M, et al. Inflammation mediated by gut microbiome alterations promotes lung cancer devel-opment and an immunosuppressed tumor microenvironment. Cancer Immunol Res. 2024;12(12):1736-52.
  26. 26..
    Tzeng A,Sangwan N,Jia M,Liu CC,Keslar KS,Downs-Kelly E, et al.Human breast microbiome correlates with prognostic features and immunological signatures in breast cancer. Genome Med.2021;13(1):60.
  27. 27..
    Coutzac C,Jouniaux JM,Paci A,Schmidt J,Mallardo D,Seck A, et al. Sys-temic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat Commun. 2020;11(1):2168.
  28. 28..
    Nomura M,Nagatomo R,Doi K,Shimizu J,Baba K,Saito T, et al. Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors. JAMA Netw Open. 2020;3(4):e202895.
  29. 29..
    Fu A,Yao B,Dong T,Chen Y,Yao J,Liu Y, et al. Tumor-resident intracel-lular microbiota promotes metastatic colonization in breast cancer. Cell.2022;185(8):1356-72.e26.
  30. 30..
    Hu J,Zhang L,Xia H,Yan Y,Zhu X,Sun F, et al. Tumor microenviron-ment remodeling after neoadjuvant immunotherapy in non-small cell lung cancer revealed by single-cell RNA sequencing. Genome Med.2023;15(1):14.
  31. 31..
    Hou K,Wu ZX,Chen XY,Wang JQ,Zhang D,Xiao C, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7(1):135.
  32. 32..
    Hermida LC,Gertz EM,Ruppin E. Predicting cancer prognosis and drug response from the tumor microbiome. Nat Commun. 2022;13(1):2896.
  33. 33..
    De Filippis F,Valentino V,Sequino G,Borriello G,Riccardi MG,Pierri B, et al. Exposure to environmental pollutants selects for xenobiotic-degrading functions in the human gut microbiome. Nat Commun.2024;15(1):4482.
  34. 34..
    Fackelmann G,Manghi P,Carlino N,Heidrich V,Piccinno G,Ricci L, et al.Gut microbiome signatures of vegan, vegetarian and omnivore diets and associated health outcomes across 21, 561 individuals. Nat Micro-biol. 2025;10(1):41-52.
  35. 35..
    Chakladar J,Wong LM,Kuo SZ,Li WT,Yu MA,Chang EY, et al. The liver microbiome is implicated in cancer prognosis and modulated by alcohol and hepatitis B. Cancers (Basel). 2020;12(6):1642.
  36. 36..
    Sun C,Hu G,Yi L,Ge W,Yang Q,Yang X, et al. Integrated analysis of facial microbiome and skin physio-optical properties unveils cutotype-dependent aging effects. Microbiome. 2024;12(1):163.
  37. 37..
    Banerjee S,Tian T,Wei Z,Shih N,Feldman MD,Peck KN, et al. Distinct microbial signatures associated with different breast cancer types. Front Microbiol. 2018;9:951.
  38. 38..
    Salter SJ,Cox MJ,Turek EM,Calus ST,Cookson WO,Moffatt MF, et al.Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol. 2014;12:87.
  39. 39..
    Liu Y,Wong CC,Ding Y,Gao M,Wen J,Lau HCH, et al. Peptostreptococ-cus anaerobius mediates anti-PD1 therapy resistance and exacerbates colorectal cancer via myeloid-derived suppressor cells in mice. Nat microbiol. 2024;9(6):1467-82.
  40. 40..
    Yamamura K,Izumi D,Kandimalla R,Sonohara F,Baba Y,Yoshida N, et al. Intratumoral Fusobacterium nucleatum levels predict therapeutic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma. Clin Cancer Res. 2019;25(20):6170-9.
  41. 41..
    Rubin H. The early history of tumor virology: Rous, RIF, and RAV. Proc Natl Acad Sci U S A. 2011;108(35):14389-96.
  42. 42..
    Elemento O. The road from Rous sarcoma virus to precision medicine. J Exp Med. 2021;218(4):e20201754.
  43. 43..
    Bister K. Discovery of oncogenes: the advent of molecular cancer research. Proc Natl Acad Sci U S A. 2015;112(50):15259-60.
  44. 44..
    Galati L,Chiantore MV,Marinaro M,Di Bonito P. Human oncogenic viruses: characteristics and prevention strategies-lessons learned from human papillomaviruses. Viruses. 2024;16(3):416.
  45. 45..
    Hassin O,Oren M. Drugging p53 in cancer: one protein, many targets.Nat Rev Drug Discov. 2023;22(2):127-44.
  46. 46..
    Xiao Q,Liu Y,Li T,Wang C,He S,Zhai L, et al. Viral oncogenesis in cancer: from mechanisms to therapeutics. Signal Transduct Target Ther. 2025;10(1):151.
  47. 47..
    Xiao Q,Liu Y,Shu X,Li Y,Zhang X,Wang C, et al. Molecular mecha-nisms of viral oncogenesis in haematological malignancies: per-spectives from metabolic reprogramming, epigenetic regulation and immune microenvironment remodeling. Exp Hematol Oncol.2025;14(1):69.
  48. 48..
    Kumar S,Metz DC,Ellenberg S,Kaplan DE,Goldberg DS. Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study. Gastroenterology. 2020;158(3):527-36.e7.
  49. 49..
    Pan KF,Li WQ,Zhang L,Liu WD,Ma JL,Zhang Y, et al. Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial. Nat Med. 2024;30(11):3250-60.
  50. 50..
    Ford AC,Yuan Y,Park JY,Forman D,Moayyedi P. Eradication therapy to prevent gastric cancer in Helicobacter pylori-positive individuals: sys-tematic review and meta-analysis of randomized controlled trials and observational studies. Gastroenterology. 2025:S0016-5085(25)00041-1..
  51. 51..
    Sibony-Benyamini H,Jbara R,Shubash Napso T,Abu-Rahmoun L,Vizen-blit D,Easton-Mor M, et al. The landscape of Helicobacter pylori-medi-ated DNA breaks links bacterial genotoxicity to its oncogenic potential.Genome Med. 2025;17(1):14.
  52. 52..
    Zeng J,Xie C,Huang Z,Cho CH,Chan H,Li Q, et al. LOX-1 acts as an N6-methyladenosine-regulated receptor for Helicobacter pylori by binding to the bacterial catalase. Nat Commun. 2024;15(1):669.
  53. 53..
    Hu W,Chen ZM,Wang Y,Yang C,Wu ZY,You LJ, et al. Single-cell RNA sequencing dissects the immunosuppressive signatures in Helicobacter pylori-infected human gastric ecosystem. Nat Commun.2025;16(1):3903.
  54. 54..
    Skoog EC,Morikis VA,Martin ME,Foster GA,Cai LP,Hansen LM, et al. CagY-dependent regulation of type IV secretion in Helicobacter pylori is associated with alterations in integrin binding. MBio.2018;9(3):e00717-e00718.
  55. 55..
    Holokai L,Chakrabarti J,Broda T,Chang J,Hawkins JA,Sundaram N, et al. Increased programmed death-ligand 1 is an early epi-thelial cell response to Helicobacter pylori infection. PLoS Pathog.2019;15(1):e1007468.
  56. 56..
    Giannakis M,Chen SL,Karam SM,Engstrand L,Gordon JI. Helicobacter pylori evolution during progression from chronic atrophic gastritis to gastric cancer and its impact on gastric stem cells. Proc Natl Acad Sci U S A. 2008;105(11):4358-63.
  57. 57..
    Wroblewski LE,Choi E,Petersen C,Delgado AG,Piazuelo MB,Romero-Gallo J, et al. Targeted mobilization of Lrig1+ gastric epithelial stem cell populations by a carcinogenic Helicobacter pylori type IV secretion system. Proc Natl Acad Sci U S A. 2019;116(39):19652-8.
  58. 58..
    Gilham C,Sargent A,Crosbie EJ,Peto J. Long-term risks of invasive cervi-cal cancer following HPV infection: follow-up of two screening cohorts in Manchester. Br J Cancer. 2023;128(10):1933-40.
  59. 59..
    Banila C,Ladoukakis E,Scibior-Bentkowska D,Santiago LR,Reuter C,Kleeman M, et al. A longitudinal pilot study in pre-menopausal women links cervicovaginal microbiome to CIN3 progression and recovery.Commun Biol. 2025;8(1):883.
  60. 60..
    Jung D-R,Choi Y,Jeong M,Singh V,Jeon SY,Seo I, et al. Metagenomic insight into the vaginal microbiome in women infected with HPV 16 and 18. NPJ Biofilms Microbiomes. 2025;11(1):105.
  61. 61..
    Huang R,Liu Z,Sun T,Zhu L. Cervicovaginal microbiome, high-risk HPV infection and cervical cancer: mechanisms and therapeutic potential.Microbiol Res. 2024;287:127857.
  62. 62..
    Ferreira RM,Pereira-Marques J,Pinto-Ribeiro I,Costa JL,Carneiro F,Machado JC, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67(2):226-36.
  63. 63..
    Coker OO,Dai Z,Nie Y,Zhao G,Cao L,Nakatsu G, et al. Mucosal microbi-ome dysbiosis in gastric carcinogenesis. Gut. 2018;67(6):1024-32.
  64. 64..
    Abate M,Vos E,Gonen M,Janjigian YY,Schattner M,Laszkowska M, et al.A novel microbiome signature in gastric cancer: a two independent cohort retrospective analysis. Ann Surg. 2022;276(4):605-15.
  65. 65..
    Yue K,Sheng D,Xue X,Zhao L,Zhao G,Jin C, et al. Bidirectional mediation effects between intratumoral microbiome and host DNA methylation changes contribute to stomach adenocarcinoma. Microbiol Spectr.2023;11(4):e0090423.
  66. 66..
    Hilmi M,Neuzillet C,Lefèvre JH,Svrcek M,Vacher S,Benhaim L, et al. Prognostic value of Fusobacterium nucleatum after abdominoper-ineal resection for anal squamous cell carcinoma. Cancers (Basel).2022;14(7):1606.
  67. 67..
    Parhi L,Alon-Maimon T,Sol A,Nejman D,Shhadeh A,Fainsod-Levi T, et al. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat Commun.2020;11(1):3259.
  68. 68..
    Parida S,Wu S,Siddharth S,Wang G,Muniraj N,Nagalingam A, et al. A procarcinogenic colon microbe promotes breast tumorigenesis and metastatic progression and concomitantly activates Notch and beta-catenin axes. Cancer Discov. 2021;11(5):1138-57.
  69. 69..
    Sitthirak S,Suksawat M,Phetcharaburanin J,Wangwiwatsin A,Klanrit P,Namwat N, et al. Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles. PeerJ. 2022;10:e13876.
  70. 70..
    Chai X,Wang J,Li H,Gao C,Li S,Wei C, et al. Intratumor microbiome fea-tures reveal antitumor potentials of intrahepatic cholangiocarcinoma.Gut Microbes. 2023;15(1):2156255.
  71. 71..
    Bullman S,Pedamallu CS,Sicinska E,Clancy TE,Zhang X,Cai D, et al.Analysis of Fusobacterium persistence and antibiotic response in colo-rectal cancer. Science. 2017;358(6369):1443-8.
  72. 72..
    Liu W,Zhang X,Xu H,Li S,Lau HC,Chen Q, et al. Microbial community heterogeneity within colorectal neoplasia and its correlation with colorectal carcinogenesis. Gastroenterology. 2021;160(7):2395-408.
  73. 73..
    Younginger BS,Mayba O,Reeder J,Nagarkar DR,Modrusan Z,Albert ML, et al. Enrichment of oral-derived bacteria in inflamed colorectal tumors and distinct associations of Fusobacterium in the mesenchymal subtype. Cell Rep Med. 2023;4(2):100920.
  74. 74..
    Jiang L,Duan B,Jia P,Zhang Y,Yan X. The role of intratumor microbi-omes in cervical cancer metastasis. Cancers (Basel). 2023;15(2):509.
  75. 75..
    Gao S,Li S,Ma Z,Liang S,Shan T,Zhang M, et al. Presence of Porphyromonas gingivalis in esophagus and its association with the clinico-pathological characteristics and survival in patients with esophageal cancer. Infect Agent Cancer. 2016;11:3.
  76. 76..
    Yamamura K,Baba Y,Nakagawa S,Mima K,Miyake K,Nakamura K, et al.Human microbiome Fusobacterium nucleatum in esophageal cancer tis-sue is associated with prognosis. Clin Cancer Res. 2016;22(22):5574-81.
  77. 77..
    Elliott DRF,Walker AW,O’Donovan M,Parkhill J,Fitzgerald RC. A non-endoscopic device to sample the oesophageal microbiota: a case-control study. Lancet Gastroenterol Hepatol. 2017;2(1):32-42.
  78. 78..
    Liu Y,Baba Y,Ishimoto T,Tsutsuki H,Zhang T,Nomoto D, et al. Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. Br J Cancer.2021;124(5):963-74.
  79. 79..
    Zhang S,Zhang S,Ma X,Zhan J,Pan C,Zhang H, et al. Intratumoral microbiome impacts immune infiltrates in tumor microenvironment and predicts prognosis in esophageal squamous cell carcinoma patients. Front Cell Infect Microbiol. 2023;13:1165790.
  80. 80..
    Wang H,Funchain P,Bebek G,Altemus J,Zhang H,Niazi F, et al. Micro-biomic differences in tumor and paired-normal tissue in head and neck squamous cell carcinomas. Genome Med. 2017;9(1):14.
  81. 81..
    Hamada M,Inaba H,Nishiyama K,Yoshida S,Yura Y,Matsumoto-Nakano M, et al. Potential role of the intratumoral microbiota in prognosis of head and neck cancer. Int J Mol Sci. 2023;24(20):15456.
  82. 82..
    Rocha M,Avenaud P,Menard A,Le Bail B,Balabaud C,Bioulac-Sage P, et al. Association of Helicobacter species with hepatitis C cirrhosis with or without hepatocellular carcinoma. Gut. 2005;54(3):396-401.
  83. 83..
    Huang JH,Wang J,Chai XQ,Li ZC,Jiang YH,Li J, et al. The intratumoral bacterial metataxonomic signature of hepatocellular carcinoma. Micro-biol Spectr. 2022;10(5):e0098322.
  84. 84..
    He Y,Zhang Q,Yu X,Zhang S,Guo W. Overview of microbial profiles in human hepatocellular carcinoma and adjacent nontumor tissues. J Transl Med. 2023;21(1):68.
  85. 85..
    Qiao K,Han J,Zhang H,Li Y,Hou X,Jia Y, et al. Intratumor Mycoplasma promotes the initiation and progression of hepatocellular carcinoma.Cell Rep. 2023;42(12):113563.
  86. 86..
    Liu Y,Kim ES,Guo H. Hepatitis B virus-related hepatocellular carcinoma exhibits distinct intratumoral microbiota and immune microenviron-ment signatures. J Med Virol. 2024;96(2):e29485.
  87. 87..
    Heidler S,Lusuardi L,Madersbacher S,Freibauer C. The microbi-ome in benign renal tissue and in renal cell carcinoma. Urol Int.2020;104(3-4):247-52.
  88. 88..
    Liss MA,Chen Y,Rodriguez R,Pruthi D,Johnson-Pais T,Wang H, et al.Microbiome within primary tumor tissue from renal cell carcinoma may be associated with PD-L1 expression of the venous tumor thrombus.Adv Urol. 2020;2020:9068068.
  89. 89..
    Wang J,Li X,Wu X,Wang Z,Zhang C,Cao G, et al. Uncovering the microbiota in renal cell carcinoma tissue using 16S rRNA gene sequencing. J Cancer Res Clin Oncol. 2021;147(2):481-91.
  90. 90..
    Kovaleva OV,Podlesnaya P,Sorokin M,Mochalnikova V,Kataev V,Khlopko YA, et al. Macrophage phenotype in combination with tumor microbiome composition predicts RCC patients’ survival: a pilot study.Biomedicines. 2022;10(7):1516.
  91. 91..
    Liu HX,Tao LL,Zhang J,Zhu YG,Zheng Y,Liu D, et al. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects.Int J Cancer. 2018;142(4):769-78.
  92. 92..
    Tsay JJ,Wu BG,Badri MH,Clemente JC,Shen N,Meyn P, et al. Airway microbiota is associated with upregulation of the PI3K pathway in lung cancer. Am J Respir Crit Care Med. 2018;198(9):1188-98.
  93. 93..
    Greathouse KL,White JR,Vargas AJ,Bliskovsky VV,Beck JA,von Muh-linen N, et al. Interaction between the microbiome and TP53 in human lung cancer. Genome Biol. 2018;19(1):123.
  94. 94..
    Dumont-Leblond N,Veillette M,Racine C,Joubert P,Duchaine C.Non-small cell lung cancer microbiota characterization: prevalence of enteric and potentially pathogenic bacteria in cancer tissues. PLoS ONE.2021;16(4):e0249832.
  95. 95..
    Tsay JJ,Wu BG,Sulaiman I,Gershner K,Schluger R,Li Y, et al. Lower airway dysbiosis affects lung cancer progression. Cancer Discov.2021;11(2):293-307.
  96. 96..
    Qiao H,Tan XR,Li H,Li JY,Chen XZ,Li YQ, et al. Association of intra-tumoral microbiota with prognosis in patients with nasopharyngeal carcinoma from 2 hospitals in china. JAMA Oncol. 2022;8(9):1301-9.
  97. 97..
    Neuzillet C,Marchais M,Vacher S,Hilmi M,Schnitzler A,Meseure D, et al. Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients. Sci Rep. 2021;11(1):7870.
  98. 98..
    Zeng B,Tan J,Guo G,Li Z,Yang L,Lao X, et al. The oral cancer micro-biome contains tumor space-specific and clinicopathology-specific bacteria. Front Cell Infect Microbiol. 2022;12:942328.
  99. 99..
    Pratap Singh R,Kumari N,Gupta S,Jaiswal R,Mehrotra D,Singh S, et al.Intratumoral microbiota changes with tumor stage and influences the immune signature of oral squamous cell carcinoma. Microbiol Spectr.2023;11(4):e0459622.
  100. 100..
    Sheng D,Yue K,Li H,Zhao L,Zhao G,Jin C, et al. The interaction between intratumoral microbiome and immunity is related to the prognosis of ovarian cancer. Microbiol Spectr. 2023;11(2):e0354922.
  101. 101..
    Banerjee S,Tian T,Wei Z,Shih N,Feldman MD,Alwine JC, et al. The ovar-ian cancer oncobiome. Oncotarget. 2017;8(22):36225-45.
  102. 102..
    Pushalkar S,Hundeyin M,Daley D,Zambirinis CP,Kurz E,Mishra A, et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov.2018;8(4):403-16.
  103. 103..
    Riquelme E,Zhang Y,Zhang L,Montiel M,Zoltan M,Dong W, et al. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell. 2019;178(4):795-806.e12.
  104. 104..
    Aykut B,Pushalkar S,Chen R,Li Q,Abengozar R,Kim JI, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL.Nature. 2019;574(7777):264-7.
  105. 105..
    Gleeson FC,Jeraldo P,Levy MJ,Murphy SJ,Mendes-Soares H,Karagouga G, et al. Composition, diversity and potential utility of intervention-naïve pancreatic cancer intratumoral microbiome signature profiling via endoscopic ultrasound. Gut. 2022;71(2):441-3.
  106. 106..
    Perry LM,Cruz SM,Kleber KT,Judge SJ,Darrow MA,Jones LB, et al.Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis. J Immu-nother Cancer. 2023;11(1):e004285.
  107. 107..
    Rustetska N,Szczepaniak M,Goryca K,Bakuła-Zalewska E,Figat M,Kowalik A, et al. The intratumour microbiota and neutrophilic inflam-mation in squamous cell vulvar carcinoma microenvironment. J Transl Med. 2023;21(1):285.
  108. 108..
    Deshpande NP,Riordan SM,Castano-Rodriguez N,Wilkins MR,Kaak-oush NO. Signatures within the esophageal microbiome are associated with host genetics, age, and disease. Microbiome. 2018;6(1):227.
  109. 109..
    Galeano Nino JL,Wu H,LaCourse KD,Kempchinsky AG,Baryiames A,Barber B, et al. Effect of the intratumoral microbiota on spatial and cel-lular heterogeneity in cancer. Nature. 2022;611(7937):810-7.
  110. 110..
    Farran M,Neppelberg E,Løes S,Aarstad AKH,Moe SE,Aarstad HJ. Peri-odontitis and dental quality of life predict long-term survival in head and neck cancer. BMC Oral Health. 2024;24(1):1406.
  111. 111..
    Tasoulas J,Farquhar DR,Sheth S,Hackman T,Yarbrough WG,Agala CB, et al. Poor oral health influences head and neck cancer patient survival:an international head and neck cancer epidemiology consortium pooled analysis. J Natl Cancer Inst. 2024;116(1):105-14.
  112. 112..
    Ahn J,Segers S,Hayes RB. Periodontal disease, Porphyromonas gingivalis serum antibody levels and orodigestive cancer mortality. Carcinogen-esis. 2012;33(5):1055-8.
  113. 113..
    Liang JQ,Wong SH,Szeto CH,Chu ES,Lau HC,Chen Y, et al. Fecal microbial DNA markers serve for screening colorectal neoplasm in asymptomatic subjects. J Gastroenterol Hepatol. 2021;36(4):1035-43.
  114. 114..
    Chakladar J,Kuo SZ,Castaneda G,Li WT,Gnanasekar A,Yu MA, et al. The pancreatic microbiome is associated with carcinogenesis and worse prognosis in males and smokers. Cancers. 2020;12(9):2672.
  115. 115..
    Peng R,Liu S,You W,Huang Y,Hu C,Gao Y, et al. Gastric microbiome alterations are associated with decreased CD8+ tissue-resident memory T cells in the tumor microenvironment of gastric cancer. Cancer Immu-nol Res. 2022;10(10):1224-40.
  116. 116..
    Lee JA,Yoo SY,Oh HJ,Jeong S,Cho NY,Kang GH, et al. Differential immune microenvironmental features of microsatellite-unstable colorectal cancers according to Fusobacterium nucleatum status. Cancer Immunol Immunother. 2021;70(1):47-59.
  117. 117..
    Gur C,Ibrahim Y,Isaacson B,Yamin R,Abed J,Gamliel M, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity.2015;42(2):344-55.
  118. 118..
    Zhang M,Zhang Y,Sun Y,Wang S,Liang H,Han Y. Intratumoral microbiota impacts the first-line treatment efficacy and survival in non-small cell lung cancer patients free of lung infection. J Healthc Eng.2022;2022:5466853.
  119. 119..
    Barlow JT,Bogatyrev SR,Ismagilov RF. A quantitative sequencing frame-work for absolute abundance measurements of mucosal and lumenal microbial communities. Nat Commun. 2020;11(1):2590.
  120. 120..
    Schwärzler J,Mayr L,Grabherr F,Tilg H,Adolph TE. Epithelial metabo-lism as a rheostat for intestinal inflammation and malignancy. Trends Cell Biol. 2024;34(11):913-27.
  121. 121..
    McCaffrey LM,Macara IG. Epithelial organization, cell polarity and tumorigenesis. Trends Cell Biol. 2011;21(12):727-35.
  122. 122..
    Grosheva I,Zheng D,Levy M,Polansky O,Lichtenstein A,Golani O, et al.High-throughput screen identifies host and microbiota regulators of intestinal barrier function. Gastroenterology. 2020;159(5):1807-23.
  123. 123..
    Maldonado-Contreras A,Birtley JR,Boll E,Zhao Y,Mumy KL,Toscano J, et al. Shigella depends on SepA to destabilize the intestinal epithelial integrity via cofilin activation. Gut Microbes. 2017;8(6):544-60.
  124. 124..
    Xu D,Liao C,Zhang B,Tolbert WD,He W,Dai Z, et al. Human enteric α-defensin 5 promotes Shigella infection by enhancing bacterial adhe-sion and invasion. Immunity. 2018;48(6):1233-44.e6.
  125. 125..
    Bloch S,Hager-Mair FF,Bacher J,Tomek MB,Janesch B,Andrukhov O, et al. Investigating the role of a Tannerella forsythia HtrA protease in host protein degradation and inflammatory response. Front Oral Health. 2024;5:1425937.
  126. 126..
    Chen W,Alshaikh A,Kim S,Kim J,Chun C,Mehrazarin S, et al. Porphyromonas gingivalis impairs oral epithelial barrier through targeting GRHL2. J Dent Res. 2019;98(10):1150-8.
  127. 127..
    Guo W,Wang P,Liu ZH,Ye P. Analysis of differential expression of tight junction proteins in cultured oral epithelial cells altered by Porphyromonas gingivalis, Porphyromonas gingivalis lipopolysaccharide, and extracellular adenosine triphosphate. Int J Oral Sci. 2018;10(1):e8.
  128. 128..
    Takeuchi H,Sasaki N,Yamaga S,Kuboniwa M,Matsusaki M,Amano A. Porphyromonas gingivalis induces penetration of lipopolysaccharide and peptidoglycan through the gingival epithelium via degradation of junctional adhesion molecule 1. PLoS Pathog. 2019;15(11):e1008124.
  129. 129..
    Wang Z,Li B,Bao L,Chen Y,Yang J,Xu F, et al. Fusobacterium nucleatum aggravates intestinal barrier impairment and colitis through IL-8 induced neutrophil chemotaxis by activating epithelial cells. J Inflamm Res. 2024;17:8407-20.
  130. 130..
    Groeger S,Jarzina F,Domann E,Meyle J. Porphyromonas gingivalis activates NFκB and MAPK pathways in human oral epithelial cells. BMC Immunol. 2017;18(1):1.
  131. 131..
    Xiang Z,Li X,Wang X,Deng B,He H,Xu M, et al. Fusobacterium nucleatum exacerbates colitis via STAT3 activation induced by acetyl-CoA accumulation. Gut Microbes. 2025;17(1):2489070.
  132. 132..
    Peng L,He Z,Chen W,Holzman IR,Lin J. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res. 2007;61(1):37-41.
  133. 133..
    Tjalsma H,Boleij A,Marchesi JR,Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Micro-biol. 2012;10(8):575-82.
  134. 134..
    Yang J,Wang X,Hu T,Huang H,Chen G,Jin B, et al. Entero-toxigenic Bacteroides fragilis contributes to intestinal barrier injury and colorectal cancer progression by mediating the BFT/STAT3/ZEB2 pathway. Cell Cycle. 2024;23(1):70-82.
  135. 135..
    Kostic AD,Chun E,Robertson L,Glickman JN,Gallini CA,Michaud M, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe.2013;14(2):207-15.
  136. 136..
    Gaiser RA,Halimi A,Alkharaan H,Lu L,Davanian H,Healy K, et al. Enrich-ment of oral microbiota in early cystic precursors to invasive pancreatic cancer. Gut. 2019;68(12):2186-94.
  137. 137..
    Kohi S,Macgregor-Das A,Dbouk M,Yoshida T,Chuidian M,Abe T, et al.Alterations in the duodenal fluid microbiome of patients with pancre-atic cancer. Clin Gastroenterol Hepatol. 2022;20(2):e196-227.
  138. 138..
    Whiteside SA,Razvi H,Dave S,Reid G,Burton JP. The microbiome of the urinary tract-a role beyond infection. Nat Rev Urol. 2015;12(2):81-90.
  139. 139..
    Ahn HK,Kim K,Park J,Kim KH. Urinary microbiome profile in men with genitourinary malignancies. Investig Clin Urol. 2022;63(5):569-76.
  140. 140..
    Jacobson D,Moore K,Gunderson C,Rowland M,Austin R,Honap TP, et al. Shifts in gut and vaginal microbiomes are associated with cancer recurrence time in women with ovarian cancer. PeerJ. 2021;9:e11574.
  141. 141..
    Kovaleva O,Podlesnaya P,Gratchev A. Resident microbiome of kidney tumors. Oncol Rev. 2024;18:1393664.
  142. 142..
    German R,Marino N,Hemmerich C,Podicheti R,Rusch DB,Stiemsma LT, et al. Exploring breast tissue microbial composition and the association with breast cancer risk factors. Breast Cancer Res. 2023;25(1):82.
  143. 143..
    Urbaniak C,Cummins J,Brackstone M,Macklaim JM,Gloor GB,Baban CK, et al. Microbiota of human breast tissue. Appl Environ Microbiol.2014;80(10):3007-14.
  144. 144..
    Morris A,Beck JM,Schloss PD,Campbell TB,Crothers K,Curtis JL, et al.Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am J Respir Crit Care Med. 2013;187(10):1067-75.
  145. 145..
    Wolfe AJ,Toh E,Shibata N,Rong R,Kenton K,Fitzgerald M, et al.Evidence of uncultivated bacteria in the adult female bladder. J Clin Microbiol. 2012;50(4):1376-83.
  146. 146..
    Mima K,Nishihara R,Qian ZR,Cao Y,Sukawa Y,Nowak JA, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.Gut. 2016;65(12):1973-80.
  147. 147..
    Yu T,Guo F,Yu Y,Sun T,Ma D,Han J, et al. Fusobacterium nucleatum pro-motes chemoresistance to colorectal cancer by modulating autophagy.Cell. 2017;170(3):548-63.e16.
  148. 148..
    Lin X,He J,Li W,Qi Y,Hu H,Zhang D, et al. Lung-targeting lysostaphin microspheres for methicillin-resistant Staphylococcus aureus pneumo-nia treatment and prevention. ACS Nano. 2021;15(10):16625-41.
  149. 149..
    Lam KC,Araya RE,Huang A,Chen Q,Di Modica M,Rodrigues RR, et al.Microbiota triggers STING-type I IFN-dependent monocyte reprogram-ming of the tumor microenvironment. Cell. 2021;184(21):5338-56.e21.
  150. 150..
    Bertocchi A,Carloni S,Ravenda PS,Bertalot G,Spadoni I,Lo Cascio A, et al. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell.2021;39(5):708-24.
  151. 151..
    Damgaard C,Magnussen K,Enevold C,Nilsson M,Tolker-Nielsen T,Holmstrup P, et al. Viable bacteria associated with red blood cells and plasma in freshly drawn blood donations. PLoS One.2015;10(3):e0120826.
  152. 152..
    Gresham HD,Lowrance JH,Caver TE,Wilson BS,Cheung AL,Lindberg FP. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J Immunol. 2000;164(7):3713-22.
  153. 153..
    Yamaguchi H,Yamada M,Uruma T,Kanamori M,Goto H,Yamamoto Y, et al. Prevalence of viable Chlamydia pneumoniae in peripheral blood mononuclear cells of healthy blood donors. Transfusion.2004;44(7):1072-8.
  154. 154..
    Yamaguchi M,Terao Y,Mori-Yamaguchi Y,Domon H,Sakaue Y,Yagi T, et al. Streptococcus pneumoniae invades erythrocytes and utilizes them to evade human innate immunity. PLoS ONE. 2013;8(10):e77282.
  155. 155..
    Païssé S,Valle C,Servant F,Courtney M,Burcelin R,Amar J, et al.Comprehensive description of blood microbiome from healthy donors assessed by 16S targeted metagenomic sequencing. Transfusion.2016;56(5):1138-47.
  156. 156..
    Whittle E,Leonard MO,Harrison R,Gant TW,Tonge DP. Multi-method characterization of the human circulating microbiome. Front Microbiol.2018;9:3266.
  157. 157..
    D’Aquila P,Giacconi R,Malavolta M,Piacenza F,Bürkle A,Villanueva MM, et al. Microbiome in blood samples from the general population recruited in the MARK-AGE project: a pilot study. Front Microbiol.2021;12:707515.
  158. 158..
    Schierwagen R,Alvarez-Silva C,Madsen MSA,Kolbe CC,Meyer C,Thomas D, et al. Circulating microbiome in blood of different circulatory compartments. Gut. 2019;68(3):578-80.
  159. 159..
    Castillo DJ,Rifkin RF,Cowan DA,Potgieter M. The healthy human blood microbiome: fact or fiction? Front Cell Infect Microbiol. 2019;9:148.
  160. 160..
    Tan CCS,Ko KKK,Chen H,Liu J,Loh M,Chia M, et al. No evidence for a common blood microbiome based on a population study of 9770 healthy humans. Nat Microbiol. 2023;8(5):973-85.
  161. 161..
    Tamburini FB,Andermann TM,Tkachenko E,Senchyna F,Banaei N,Bhatt AS. Precision identification of diverse bloodstream pathogens in the gut microbiome. Nat Med. 2018;24(12):1809-14.
  162. 162..
    Li Y,Chang RB,Stone ML,Delman D,Markowitz K,Xue Y, et al. Multi-modal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer. Cell Rep Med. 2024;5(2):101397.
  163. 163..
    Anderson NM,Simon MC. The tumor microenvironment. Curr Biol.2020;30(16):R921-5.
  164. 164..
    Litvak Y,Mon KKZ,Nguyen H,Chanthavixay G,Liou M,Velazquez EM, et al. Commensal Enterobacteriaceae protect against Salmonella colonization through oxygen competition. Cell Host Microbe.2019;25(1):128-39.e5.
  165. 165..
    Harimoto T,Deb D,Danino T. A rapid screening platform to coculture bacteria within tumor spheroids. Nat Protoc. 2022;17(10):2216-39.
  166. 166..
    Li S,Xia H,Wang Z,Zhang X,Song T,Li J, et al. Intratumoral micro-bial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC. Hepatology.2023;78(4):1079-91.
  167. 167..
    Gurbatri CR,Lia I,Vincent R,Coker C,Castro S,Treuting PM, et al.Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies. Sci Transl Med. 2020;12(530):eaax0876.
  168. 168..
    Israelsen WJ,Vander Heiden MG. ATP consumption promotes cancer metabolism. Cell. 2010;143(5):669-71.
  169. 169..
    Battaglia TW,Mimpen IL,Traets JJH,van Hoeck A,Zeverijn LJ,Geurts BS, et al. A pan-cancer analysis of the microbiome in metastatic cancer.Cell. 2024;187(9):2324-35.e19.
  170. 170..
    Tan Q,Ma X,Yang B,Liu Y,Xie Y,Wang X, et al. Periodontitis pathogen Porphyromonas gingivalis promotes pancreatic tumorigenesis via neutrophil elastase from tumor-associated neutrophils. Gut Microbes.2022;14(1):2073785.
  171. 171..
    Zhu H,Sydor AM,Boddy KC,Coyaud E,Laurent EMN,Au A, et al. Salmonella exploits membrane reservoirs for invasion of host cells. Nat Commun. 2024;15(1):3120.
  172. 172..
    Russo BC,Duncan-Lowey JK,Chen P,Goldberg MB. The type 3 secretion system requires actin polymerization to open translocon pores. PLoS Pathog. 2021;17(9):e1009932.
  173. 173..
    Hu B,Lara-Tejero M,Kong Q,Galán JE,Liu J. In situ molecular architec-ture of the Salmonella type III secretion machine. Cell. 2017;168(6):1065-74.e10.
  174. 174..
    Feltham L,Moran J,Goldrick M,Lord E,Spiller DG,Cavet JS, et al.Bacterial aggregation facilitates internalin-mediated invasion of Listeria monocytogenes. Front Cell Infect Microbiol. 2024;14:1411124.
  175. 175..
    Gaillard JL,Berche P,Frehel C,Gouin E,Cossart P. Entry of L. mono-cytogenes into cells is mediated by internalin, a repeat protein reminiscent of surface antigens from gram-positive cocci. Cell.1991;65(7):1127-41.
  176. 176..
    Hardt WD,Chen LM,Schuebel KE,Bustelo XR,Galan JES. typhimurium encodes an activator of Rho GTPases that induces membrane ruffling and nuclear responses in host cells. Cell. 1998;93(5):815-26.
  177. 177..
    Cossart P,Roy CR. Manipulation of host membrane machinery by bacterial pathogens. Curr Opin Cell Biol. 2010;22(4):547-54.
  178. 178..
    Ribet D,Cossart P. How bacterial pathogens colonize their hosts and invade deeper tissues. Microbes Infect. 2015;17(3):173-83.
  179. 179..
    Chagnot C,Listrat A,Astruc T,Desvaux M. Bacterial adhesion to animal tissues: protein determinants for recognition of extracellular matrix components. Cell Microbiol. 2012;14(11):1687-96.
  180. 180..
    Grabosch C,Hartmann M,Schmidt-Lassen J,Lindhorst TK. Squaric acid monoamide mannosides as ligands for the bacterial lectin FimH:covalent inhibition or not? ChemBioChem. 2011;12(7):1066-74.
  181. 181..
    Mathelié-Guinlet M,Viela F,Alfeo MJ,Pietrocola G,Speziale P,Dufrêne YF. Single-molecule analysis demonstrates stress-enhanced binding between Staphylococcus aureus surface protein IsdB and host cell integrins. Nano Lett. 2020;20(12):8919-25.
  182. 182..
    Talukdar PK,Negretti NM,Turner KL,Konkel ME. Molecular dissection of the Campylobacter jejuni CadF and FlpA virulence proteins in binding to host cell fibronectin. Microorganisms. 2020;8(3):389.
  183. 183..
    Walker C,Mojares E,Del Rio HA. Role of extracellular matrix in develop-ment and cancer progression. Int J Mol Sci. 2018;19(10):3028.
  184. 184..
    Giussani M,Triulzi T,Sozzi G,Tagliabue E. Tumor extracellular matrix remodeling: new perspectives as a circulating tool in the diagnosis and prognosis of solid tumors. Cells. 2019;8(2):81.
  185. 185..
    Karamanos NK,Theocharis AD,Neill T,Iozzo RV. Matrix modeling and remodeling: a biological interplay regulating tissue homeostasis and diseases. Matrix Biol. 2019;75-76:1-11.
  186. 186..
    Abed J,Emgard JE,Zamir G,Faroja M,Almogy G,Grenov A, et al. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrich-ment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe.2016;20(2):215-25.
  187. 187..
    Long X,Wong CC,Tong L,Chu ESH,Ho Szeto C,Go MYY, et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat Microbiol. 2019;4(12):2319-30.
  188. 188..
    Fukushima S,Shimohata T,Inoue Y,Kido J,Uebanso T,Mawatari K, et al.Recruitment of LC3 by Campylobacter jejuni to bacterial invasion site on host cells via the Rac1-mediated signaling pathway. Front Cell Infect Microbiol. 2022;12:829682.
  189. 189..
    Robertin S,Brokatzky D,Lobato-Márquez D,Mostowy S. Regulation of integrin α5β1-mediated Staphylococcus aureus cellular invasion by the septin cytoskeleton. Eur J Cell Biol. 2023;102(4):151359.
  190. 190..
    Zhang Z,Li J,Jiao S,Han G,Zhu J,Liu T. Functional and clinical charac-teristics of focal adhesion kinases in cancer progression. Front Cell Dev Biol. 2022;10:1040311.
  191. 191..
    Arriagada C,Silva P,Millet M,Solano L,Moraga C,Torres VA. Focal adhe-sion kinase-dependent activation of the early endocytic protein Rab5 is associated with cell migration. J Biol Chem. 2019;294(34):12836-45.
  192. 192..
    Yilmaz O,Watanabe K,Lamont RJ. Involvement of integrins in fimbriae-mediated binding and invasion by Porphyromonas gingivalis. Cell Microbiol. 2002;4(5):305-14.
  193. 193..
    Kyei GB,Vergne I,Chua J,Roberts E,Harris J,Junutula JR, et al. Rab14 is critical for maintenance of Mycobacterium tuberculosis phagosome maturation arrest. EMBO J. 2006;25(22):5250-9.
  194. 194..
    Jaumouille V,Cartagena-Rivera AX,Waterman CM. Coupling of beta2 integrins to actin by a mechanosensitive molecular clutch drives complement receptor-mediated phagocytosis. Nat Cell Biol.2019;21(11):1357-69.
  195. 195..
    Kellermann M,Scharte F,Hensel M. Manipulation of host cell orga-nelles by intracellular pathogens. Int J Mol Sci. 2021;22(12):6484.
  196. 196..
    Finn CE,Chong A,Cooper KG,Starr T,Steele-Mortimer O. A second wave of Salmonella T3SS1 activity prolongs the lifespan of infected epithelial cells. PLoS Pathog. 2017;13(4):e1006354.
  197. 197..
    Kawabata M,Matsuo H,Koito T,Murata M,Kubori T,Nagai H, et al. Legionella hijacks the host Golgi-to-ER retrograde pathway for the association of Legionella-containing vacuole with the ER. PLoS Pat-hog. 2021;17(3):e1009437.
  198. 198..
    Vaughn B,Abu KY. Idiosyncratic biogenesis of intracellular pathogens-containing vacuoles. Front Cell Infect Microbiol.2021;11:722433.
  199. 199..
    Radtke AL,Anderson KL,Davis MJ,DiMagno MJ,Swanson JA,O’Riordan MX. Listeria monocytogenes exploits cystic fibrosis trans-membrane conductance regulator (CFTR) to escape the phagosome. Proc Natl Acad Sci U S A. 2011;108(4):1633-8.
  200. 200..
    Burton PR,Kordova N,Paretsky D. Electron microscopic studies of the rickettsia Coxiella burneti: entry, lysosomal response, and fate of rickettsial DNA in L-cells. Can J Microbiol. 1971;17(2):143-50.
  201. 201..
    Akporiaye ET,Rowatt JD,Aragon AA,Baca OG. Lysosomal response of a murine macrophage-like cell line persistently infected with Coxiella burnetii. Infect Immun. 1983;40(3):1155-62.
  202. 202..
    Heinzen RA,Scidmore MA,Rockey DD,Hackstadt T. Differential interaction with endocytic and exocytic pathways distinguish para-sitophorous vacuoles of Coxiella burnetii and Chlamydia trachomatis.Infect Immun. 1996;64(3):796-809.
  203. 203..
    Atwal S,Wongsantichon J,Giengkam S,Saharat K,Pittayasathornthun YJ,Chuenklin S, et al. The obligate intracellular bacterium Orientia tsutsugamushi differentiates into a developmentally distinct extracel-lular state. Nat Commun. 2022;13(1):3603.
  204. 204..
    Cossart P,Sansonetti PJ. Bacterial invasion: the paradigms of enteroin-vasive pathogens. Science. 2004;304(5668):242-8.
  205. 205..
    Venkatesan M,Zhang N,Marteau B,Yajima Y,De Zarate Garcia NO,Fang Z, et al. Spatial subcellular organelle networks in single cells. Sci Rep. 2023;13(1):5374.
  206. 206..
    Laan SNJ,Dirven RJ,Bürgisser PE,Eikenboom J,Bierings R. Auto-mated segmentation and quantitative analysis of organelle morphology, localization and content using Cell Profiler. PLoS ONE.2023;18(6):e0278009.
  207. 207..
    Aman Y,Schmauck-Medina T,Hansen M,Morimoto RI,Simon AK,Bjedov I, et al. Autophagy in healthy aging and disease. Nat Aging.2021;1(8):634-50.
  208. 208..
    Chiu HC,Kulp SK,Soni S,Wang D,Gunn JS,Schlesinger LS, et al.Eradication of intracellular Salmonella enterica serovar Typhimurium with a small-molecule, host cell-directed agent. Antimicrob Agents Chemother. 2009;53(12):5236-44.
  209. 209..
    Junkins RD,Shen A,Rosen K,McCormick C,Lin TJ. Autophagy enhances bacterial clearance during P. aeruginosa lung infection. PLoS ONE.2013;8(8):e72263.
  210. 210..
    Birmingham CL,Canadien V,Gouin E,Troy EB,Yoshimori T,Cossart P, et al. Listeria monocytogenes evades killing by autophagy during colonization of host cells. Autophagy. 2007;3(5):442-51.
  211. 211..
    Bélanger M,Rodrigues PH,JrDunn WA,Progulske-Fox A. Autophagy: a highway for Porphyromonas gingivalis in endothelial cells. Autophagy.2006;2(3):165-70.
  212. 212..
    Bauckman KA,Mysorekar IU. Ferritinophagy drives uropathogenic Escherichia coli persistence in bladder epithelial cells. Autophagy.2016;12(5):850-63.
  213. 213..
    Lucas C,Salesse L,Hoang MHT,Bonnet M,Sauvanet P,Larabi A, et al.Autophagy of intestinal epithelial cells inhibits colorectal carcinogen-esis induced by colibactin-producing Escherichia coli in ApcMin/+ mice.Gastroenterology. 2020;158(5):1373-88.
  214. 214..
    Larabi A,Barnich N,Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy. 2020;16(1):38-51.
  215. 215..
    Xie M,Tang Q,Yu S,Sun J,Mei F,Zhao J, et al. Porphyromonas gingivalis disrupts vascular endothelial homeostasis in a TLR-NF-kappaB axis dependent manner. Int J Oral Sci. 2020;12(1):28.
  216. 216..
    Xuan M,Gu X,Liu Y,Yang L,Li Y,Huang D, et al. Intratumoral micro-organisms in tumors of the digestive system. Cell Commun Signal.2024;22(1):69.
  217. 217..
    Hurst R,Brewer DS,Gihawi A,Wain J,Cooper CS. Cancer invasion and anaerobic bacteria: new insights into mechanisms. J Med Microbiol.2024;73(3):001817.
  218. 218..
    Yang L,Li A,Wang Y,Zhang Y. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct Target Ther. 2023;8(1):35.
  219. 219..
    Pleguezuelos-Manzano C,Puschhof J,Rosendahl Huber A,Van Hoeck A,Wood HM,Nomburg J, et al. Mutational signature in colorectal cancer caused by genotoxic pks+ E coli. Nature. 2020;580(7802):269-73.
  220. 220..
    Tremblay W,Mompart F,Lopez E,Quaranta M,Bergoglio V,Hashim S, et al. Cytolethal distending toxin promotes replicative stress leading to genetic instability transmitted to daughter cells. Front Cell Dev Biol.2021;9:656795.
  221. 221..
    Wang X,Allen TD,May RJ,Lightfoot S,Houchen CW,Huycke MM. Enterococcus faecalis induces aneuploidy and tetraploidy in colonic epithe-lial cells through a bystander effect. Cancer Res. 2008;68(23):9909-17.
  222. 222..
    Park HE,Kim JH,Cho NY,Lee HS,Kang GH. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma. Virchows Arch. 2017;471(3):329-36.
  223. 223..
    Guo S,Chen F,Li L,Dou S,Li Q,Huang Y, et al. Intracellular Fusobacterium nucleatum infection increases METTL3-mediated m6A methylation to promote the metastasis of esophageal squamous cell carcinoma. J Adv Res. 2024;61:165-78.
  224. 224..
    Murata-Kamiya N,Kurashima Y,Teishikata Y,Yamahashi Y,Saito Y,Higashi H, et al. Helicobacter pylori CagA interacts with E-cadherin and deregu-lates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene. 2007;26(32):4617-26.
  225. 225..
    Franco AT,Israel DA,Washington MK,Krishna U,Fox JG,Rogers AB, et al.Activation of beta-catenin by carcinogenic Helicobacter pylori. Proc Natl Acad Sci U S A. 2005;102(30):10646-51.
  226. 226..
    Rubinstein MR,Wang X,Liu W,Hao Y,Cai G,Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cad-herin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe.2013;14(2):195-206.
  227. 227..
    Buti L,Spooner E,Van der Veen AG,Rappuoli R,Covacci A,Ploegh HL. Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor path-way of the host. Proc Natl Acad Sci U S A. 2011;108(22):9238-43.
  228. 228..
    Siegl C,Prusty BK,Karunakaran K,Wischhusen J,Rudel T. Tumor sup-pressor p53 alters host cell metabolism to limit Chlamydia trachomatis infection. Cell Rep. 2014;9(3):918-29.
  229. 229..
    Bergounioux J,Elisee R,Prunier AL,Donnadieu F,Sperandio B,Sanson-etti P, et al. Calpain activation by the Shigella flexneri effector VirA regu-lates key steps in the formation and life of the bacterium’s epithelial niche. Cell Host Microbe. 2012;11(3):240-52.
  230. 230..
    Hui B,Zhou C,Xu Y,Wang R,Dong Y,Zhou Y, et al. Exosomes secreted by Fusobacterium nucleatum-infected colon cancer cells transmit resistance to oxaliplatin and 5-FU by delivering hsa_circ_0004085. J Nanobiotechnology. 2024;22(1):62.
  231. 231..
    Chen F,Yang J,Guo Y,Su D,Sheng Y,Wu Y. Integrating bulk and single-cell RNA sequencing data reveals the relationship between intratumor microbiome signature and host metabolic heterogeneity in breast cancer. Front Immunol. 2023;14:1140995.
  232. 232..
    Thiele Orberg E,Fan H,Tam AJ,Dejea CM,Destefano Shields CE,Wu S, et al. The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunol.2017;10(2):421-33.
  233. 233..
    Jin C,Lagoudas GK,Zhao C,Bullman S,Bhutkar A,Hu B, et al. Com-mensal microbiota promote lung cancer development via gammadelta T cells. Cell. 2019;176(5):998-1013.
  234. 234..
    Alam A,Levanduski E,Denz P,Villavicencio HS,Bhatta M,Alhorebi L, et al. Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. Cancer Cell. 2022;40(2):153-67.e11.
  235. 235..
    Gao Y,Zou T,Xu P,Wang Y,Jiang Y,Chen YX, et al. Fusobacterium nucleatum stimulates cell proliferation and promotes PD-L1 expression via IFIT1-related signal in colorectal cancer. Neoplasia. 2023;35:100850.
  236. 236..
    Ugai T,Shimizu T,Kawamura H,Ugai S,Takashima Y,Usui G, et al. Inverse relationship between Fusobacterium nucleatum amount and tumor CD274 (PD-L1) expression in colorectal carcinoma. Clin Transl Immunol-ogy. 2023;12(8):e1453.
  237. 237..
    Li Y,Xing S,Chen F,Li Q,Dou S,Huang Y, et al. Intracellular Fusobacterium nucleatum infection attenuates antitumor immunity in esophageal squamous cell carcinoma. Nat Commun. 2023;14(1):5788.
  238. 238..
    Yuan X,Liu Y,Li G,Lan Z,Ma M,Li H, et al. Blockade of immune-check-point B7-H4 and lysine demethylase 5B in esophageal squamous cell carcinoma confers protective immunity against P gingivalis infection.Cancer Immunol Res. 2019;7(9):1440-56.
  239. 239..
    Zhou Y,Qin Y,Ma J,Li Z,Heng W,Zhang L, et al. Heat-killed Prevotella intermedia promotes the progression of oral squamous cell carcinoma by inhibiting the expression of tumor suppressors and affecting the tumor microenvironment. Exp Hematol Oncol. 2024;13(1):33.
  240. 240..
    Vetizou M,Pitt JM,Daillere R,Lepage P,Waldschmitt N,Flament C, et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079-84.
  241. 241..
    Gao Y,Bi D,Xie R,Li M,Guo J,Liu H, et al. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal Transduct Target Ther. 2021;6(1):398.
  242. 242..
    Matson V,Fessler J,Bao R,Chongsuwat T,Zha Y,Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in meta-static melanoma patients. Science. 2018;359(6371):104-8.
  243. 243..
    Hamada T,Zhang X,Mima K,Bullman S,Sukawa Y,Nowak JA, et al. Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status. Cancer Immunol Res. 2018;6(11):1327-36.
  244. 244..
    Livyatan I,Straussman R. A spatial perspective on bacteria in tumours.Nature. 2022;611(7937):674-5.
  245. 245..
    Kalaora S,Nagler A,Nejman D,Alon M,Barbolin C,Barnea E, et al. Identi-fication of bacteria-derived HLA-bound peptides in melanoma. Nature.2021;592(7852):138-43.
  246. 246..
    Najibi M,Honwad HH,Moreau JA,Becker SM,Irazoqui JE. A novel NOX/PHOX-CD38-NAADP-TFEB axis important for macrophage activation during bacterial phagocytosis. Autophagy. 2022;18(1):124-41.
  247. 247..
    Harusato A,Viennois E,Etienne-Mesmin L,Matsuyama S,Abo H,Osuka S, et al. Early-life microbiota exposure restricts myeloid-derived suppressor cell-driven colonic tumorigenesis. Cancer Immunol Res.2019;7(4):544-51.
  248. 248..
    Montalban-Arques A,Katkeviciute E,Busenhart P,Bircher A,Wirbel J,Zeller G, et al. Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors. Cell Host Microbe.2021;29(10):1573-88.e7.
  249. 249..
    Zhu Z,Cai J,Hou W,Xu K,Wu X,Song Y, et al. Microbiome and spatially resolved metabolomics analysis reveal the anticancer role of gut Akkermansia muciniphila by crosstalk with intratumoral microbiota and reprogramming tumoral metabolism in mice. Gut Microbes.2023;15(1):2166700.
  250. 250..
    Konishi H,Fujiya M,Tanaka H,Ueno N,Moriichi K,Sasajima J, et al. Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. Nat Commun. 2016;7:12365.
  251. 251..
    Colbert LE,El Alam MB,Wang R,Karpinets T,Lo D,Lynn EJ, et al. Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring. Cancer Cell. 2023;41(11):1945-62.e11.
  252. 252..
    Jones DJ,Bunn F,Bell-Syer SV. Prophylactic antibiotics to prevent surgi-cal site infection after breast cancer surgery. Cochrane Database Syst Rev. 2014;3:5360.
  253. 253..
    Kiran RP,Murray AC,Chiuzan C,Estrada D,Forde K. Combined preopera-tive mechanical bowel preparation with oral antibiotics significantly reduces surgical site infection, anastomotic leak, and ileus after colorec-tal surgery. Ann Surg. 2015;262(3):416-25.
  254. 254..
    Kaibori M,Matsui K,Shimada M,Kubo S,Hasegawa K. Update on perio-perative management of patients undergoing surgery for liver cancer.Ann Gastroenterol Surg. 2022;6(3):344-54.
  255. 255..
    Yuan X,Zhou F,Wang H,Xu X,Xu S,Zhang C, et al. Systemic antibiotics increase microbiota pathogenicity and oral bone loss. Int J Oral Sci.2023;15(1):4.
  256. 256..
    Tarantino G,Citro V. Could adverse effects of antibiotics due to their use/misuse be linked to some mechanisms related to nonalcoholic fatty liver disease? Int J Mol Sci. 2024;25(4):1993.
  257. 257..
    Stein-Thoeringer CK,Saini NY,Zamir E,Blumenberg V,Schubert ML,Mor U, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med.2023;29(4):906-16.
  258. 258..
    Fahrmann JF,Saini NY,Chia-Chi C,Irajizad E,Strati P,Nair R, et al. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med.2022;3(11):100720.
  259. 259..
    McKee AM,Kirkup BM,Madgwick M,Fowler WJ,Price CA,Dreger SA, et al. Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth. Science. 2021;24(9):103012.
  260. 260..
    Smith M,Dai A,Ghilardi G,Amelsberg KV,Devlin SM,Pajarillo R, et al.Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022;28(4):713-23.
  261. 261..
    Pinato DJ,Howlett S,Ottaviani D,Urus H,Patel A,Mineo T, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol.2019;5(12):1774-8.
  262. 262..
    Pirini F,Cortesi M,Tumedei MM,Zanoni M,Ravaioli S,Bravaccini S. Tumor resident microbiota and response to therapies: an insight on tissue bacterial microbiota. Front Cell Dev Biol. 2022;10:1048360.
  263. 263..
    Muñoz KA,Ulrich RJ,Vasan AK,Sinclair M,Wen PC,Holmes JR, et al. A gram-negative-selective antibiotic that spares the gut microbiome.Nature. 2024;630(8016):429-36.
  264. 264..
    LaCourse KD,Zepeda-Rivera M,Kempchinsky AG,Baryiames A,Minot SS,Johnston CD, et al. The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota. Cell Rep. 2022;41(7):111625.
  265. 265..
    Wang S,Chan SY,Deng Y,Khoo BL,Chua SL. Oxidative stress induced by Etoposide anti-cancer chemotherapy drives the emergence of tumor-associated bacteria resistance to fluoroquinolones. J Adv Res.2024;55:33-44.
  266. 266..
    Ilhami FB,Huang SY,Cheng CC. Multi-biofunctional silver-containing metallosupramolecular nanogels for efficient antibacterial treatment and selective anticancer therapy. Acta Biomater. 2022;151:576-87.
  267. 267..
    Kang X,Bu F,Feng W,Liu F,Yang X,Li H, et al. Dual-cascade responsive nanoparticles enhance pancreatic cancer therapy by eliminating tumor-resident intracellular bacteria. Adv Mater. 2022;34(49):e2206765.
  268. 268..
    Xie S,Wei L,Liu Y,Meng J,Cao W,Qiu B, et al. Size-tunable nanogels for cascaded release of metronidazole and chemotherapeutic agents to combat Fusobacterium nucleatum-infected colorectal cancer. J Control Release. 2024;365:16-28.
  269. 269..
    Liu X,Sun M,Pu F,Ren J,Qu X. Transforming intratumor bacteria into immunopotentiators to reverse cold tumors for enhanced immuno-chemodynamic therapy of triple-negative breast cancer. J Am Chem Soc. 2023;145(48):26296-307.
  270. 270..
    Geng S,Guo P,Li X,Shi Y,Wang J,Cao M, et al. Biomimetic nanovehicle-enabled targeted depletion of intratumoral Fusobacterium nucleatum synergizes with PD-L1 blockade against breast cancer. ACS Nano.2024;18(12):8971-87.
  271. 271..
    Liu J,Li B,Li L,Ming X,Xu ZP. Advances in nanomaterials for immu-notherapeutic improvement of cancer chemotherapy. Small.2024;20(38):e2403024.
  272. 272..
    Mellman I,Chen DS,Powles T,Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity.2023;56(10):2188-205.
  273. 273..
    Fluckiger A,Daillère R,Sassi M,Sixt BS,Liu P,Loos F, et al. Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage. Science. 2020;369(6506):936-42.
  274. 274..
    Wang M,Rousseau B,Qiu K,Huang G,Zhang Y,Su H, et al. Killing tumor-associated bacteria with a liposomal antibiotic generates neo-antigens that induce anti-tumor immune responses. Nat Biotechnol.2024;42(8):1263-74.
  275. 275..
    Sudaarsan ASK,Ghosh AR. Appraisal of postbiotics in cancer therapy.Front Pharmacol. 2024;15:1436021.
  276. 276..
    Morita A,Ichihara E,Inoue K,Fujiwara K,Yokoyama T,Harada D, et al.Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer. Int J Cancer. 2024;154(9):1607-15.
  277. 277..
    Jiang S,Ma W,Ma C,Zhang Z,Zhang W,Zhang J. An emerging strategy:probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome. Gut Microbes. 2024;16(1):2341717.
  278. 278..
    Chen P,Yang C,Ren K,Xu M,Pan C,Ye X, et al. Modulation of gut microbiota by probiotics to improve the efficacy of immunotherapy in hepatocellular carcinoma. Front Immunol. 2024;15:1504948.
  279. 279..
    Kvakova M,Kamlarova A,Stofilova J,Benetinova V,Bertkova I. Probiotics and postbiotics in colorectal cancer: prevention and complementary therapy. World J Gastroenterol. 2022;28(27):3370-82.
  280. 280..
    Hibberd AA,Lyra A,Ouwehand AC,Rolny P,Lindegren H,Cedgård L, et al. Intestinal microbiota is altered in patients with colon cancer and modified by probiotic intervention. BMJ Open Gastroenterol.2017;4(1):e000145.
  281. 281..
    Zhang JW,Du P,Gao J,Yang BR,Fang WJ,Ying CM. Preoperative pro-biotics decrease postoperative infectious complications of colorectal cancer. Am J Med Sci. 2012;343(3):199-205.
  282. 282..
    Gianotti L,Morelli L,Galbiati F,Rocchetti S,Coppola S,Beneduce A, et al. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol.2010;16(2):167-75.
  283. 283..
    Zaharuddin L,Mokhtar NM,Muhammad Nawawi KN,Raja Ali RA. A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer. BMC Gastroenterol. 2019;19(1):131.
  284. 284..
    Rafter J,Bennett M,Caderni G,Clune Y,Hughes R,Karlsson PC, et al.Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr. 2007;85(2):488-96.
  285. 285..
    Mego M,Chovanec J,Vochyanova-Andrezalova I,Konkolovsky P,Miku-lova M,Reckova M, et al. Prevention of irinotecan induced diarrhea by probiotics: a randomized double blind, placebo controlled pilot study.Complement Ther Med. 2015;23(3):356-62.
  286. 286..
    Shi Y,Zheng W,Yang K,Harris KG,Ni K,Xue L, et al. Intratumoral accu-mulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J Exp Med. 2020;217(5):e20192282.
  287. 287..
    Fong W,Li Q,Ji F,Liang W,Lau HCH,Kang X, et al. Lactobacillus gallinarum-derived metabolites boost anti-PD1 efficacy in colorectal cancer by inhibiting regulatory T cells through modulating IDO1/Kyn/AHR axis. Gut. 2023;72(12):2272-85.
  288. 288..
    Routy B,Le Chatelier E,Derosa L,Duong CPM,Alou MT,Daillère R, et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91-7.
  289. 289..
    Han ZY,Fu ZJ,Wang YZ,Zhang C,Chen QW,An JX, et al. Probiotics functionalized with a gallium-polyphenol network modulate the intratumor microbiota and promote anti-tumor immune responses in pancreatic cancer. Nat Commun. 2024;15(1):7096.
  290. 290..
    Spencer CN,McQuade JL,Gopalakrishnan V,McCulloch JA,Vetizou M,Cogdill AP, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science.2021;374(6575):1632-40.
  291. 291..
    Nguyen DH,Chong A,Hong Y,Min JJ. Bioengineering of bacteria for cancer immunotherapy. Nat Commun. 2023;14(1):3553.
  292. 292..
    Tao C,Miao X,Yan J,Xiao X,Wu R,Cao Q, et al. Hypoxia-targeted and spatial-selective tumor suppression by near infrared nanoantenna sensitized engineered bacteria. Acta Biomater. 2023;170:442-52.
  293. 293..
    Wei Y,Zhang Z,Xue T,Lin Z,Chen X,Tian Y, et al. In situ synthesis of an immune-checkpoint blocker from engineered bacteria elicits a potent antitumor response. ACS Synth Biol. 2024;13(6):1679-93.
  294. 294..
    Paterson Y,Guirnalda PD,Wood LM. Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy. Semin Immunol. 2010;22(3):183-9.
  295. 295..
    van Pijkeren JP,Morrissey D,Monk IR,Cronin M,Rajendran S,O’Sullivan GC, et al. A novel Listeria monocytogenes-based DNA delivery system for cancer gene therapy. Hum Gene Ther. 2010;21(4):405-16.
  296. 296..
    Kang SR,Nguyen DH,Yoo SW,Min JJ. Bacteria and bacterial deriva-tives as delivery carriers for immunotherapy. Adv Drug Deliv Rev.2022;181:114085.
  297. 297..
    Gniadek TJ,Augustin L,Schottel J,Leonard A,Saltzman D,Greeno E, et al. A phase I, dose escalation, single dose trial of oral attenuated Salmonella typhimurium containing human IL-2 in patients with metastatic gastrointestinal cancers. J Immunother. 2020;43(7):217-21.
  298. 298..
    Lenis AT,Lec PM,Chamie K,Mshs MD. Bladder cancer: a review. JAMA.2020;324(19):1980-91.
  299. 299..
    Chang Z,Guo X,Li X,Wang Y,Zang Z,Pei S, et al. Bacterial immuno-therapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization. Cell. 2025;188(7):1842-57.
  300. 300..
    Canale FP,Basso C,Antonini G,Perotti M,Li N,Sokolovska A, et al. Meta-bolic modulation of tumours with engineered bacteria for immuno-therapy. Nature. 2021;598(7882):662-6.
  301. 301..
    Dai Z,Zhao W,Cao L,Zhu Z,Xia Z,Xia L. Engineered probiotic E. coli Nissle 1917 for release PTEN to improve the tumor microenvironment and suppress tumor growth. Biotechnol Lett. 2024;46(6):1237-47.
  302. 302..
    Liao J,Pan H,Huang G,Gong H,Chen Z,Yin T, et al. T cell cascade regulation initiates systemic antitumor immunity through living drug factory of anti-PD-1/IL-12 engineered probiotics. Cell Rep.2024;43(4):114086.
  303. 303..
    Caproni E,Corbellari R,Tomasi M,Isaac SJ,Tamburini S,Zanella I, et al.Anti-tumor efficacy of in situ vaccination using bacterial outer mem-brane vesicles. Cancers (Basel). 2023;15(13):3328.
  304. 304..
    Zhang J,Wan S,Zhou H,Du J,Li Y,Zhu H, et al. Programmed nanocloak of commensal bacteria-derived nanovesicles amplify strong immunore-activity against tumor growth and metastatic progression. ACS Nano.2024:18(13):9613-26.
  305. 305..
    Green JJ,Elisseeff JH. Mimicking biological functionality with polymers for biomedical applications. Nature. 2016;540(7633):386-94.

Leia o texto completo

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website